Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen

BACKGROUND: Up to one-quarter of breast cancer patients suffer clinically significant depression in the year after diagnosis, which may respond to intervention. About half may be prescribed a psychotropic medication, such as a selective serotonin reuptake inhibitor (SSRI), while completing breast ca...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Lash, Timothy L., Cronin-Fenton, Deirdre, Ahern, Thomas P., Rosenberg, Carol L., Lunetta, Kathryn L., Silliman, Rebecca A., Hamilton-Dutoit, Stephen, Garne, Jens Peter, Ewertz, Marianne, Sørensen, Henrik Toft, Pedersen, Lars
Format: Artigo
Idioma:Inglês
Publicat: 2010
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2892037/
https://ncbi.nlm.nih.gov/pubmed/20156115
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/02841860903575273
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars